Global Capecitabine research
Global Capecitabine research

Capecitabine Comprehensive Study by Type (500 mg, 150 mg), Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Others), Drug Formulation (Tablets, Capsule) Players and Region - Global Market Outlook to 2024

Capecitabine Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 249 Pages 165 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Capecitabine Market Overview:
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment that reduces or prevents the progression of cancer cells. This drug is used for the treatment of cancers such as colorectal cancer, breast cancer, and gastric cancer. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows the growth of tumor tissue. Some of the key players profiled in the study are Dr Reddy Laboratories Ltd (India), Fresenius SE & Co. KGaA (Germany), Cipla Inc. (India), Genentech, Inc. (United States), F. Hoffmann-La Roche (Switzerland), Sandoz (Germany), Ranbaxy Laboratories Ltd. (India), Zentiva N.V. (Czechia), Teva Pharma B.V. (Netherlands) and Accord Healthcare Ltd. (India).

On the basis of geography, the market of Capecitabine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Formulation, the sub-segment i.e. Tablets will boost the Capecitabine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Geriatric Population
  • Rise in Healthcare Expenditure and an Increase in Investment in Cancer Treatment or Assisted Programs by Governments


Restraints
  • Availability of Generic Drugs and Patent Expiration of Branded Drugs
  • Stringent Government Regulations Related to the Safety
  • High Cost of Capecitabine

Opportunities
  • Huge Investment in R&D in Development of Drugs by Major Market Players
  • Growing Health Care Industry

Challenges
  • Lack of Awareness among the Consumers


Major Market Developments:


In April 2019, the Emcure Pharmaceutical (India) Company has launched generic breast cancer medicine, which is used to treat HER 2 negative patients. Hence, it will benefit the increased product portfolio of the company in the future.
According to the National Cancer Institute around 135,430 people are estimated to suffer from colon and rectum cancer and 50,260 people died of colon and rectum cancer in 2017.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of a competitive advantage through combined collaborations.

Target Audience:
Manufacturers of Capecitabine, Suppliers of Capecitabine, Wholesalers, Distributors and Retailers of Capecitabine, Healthcare Industry, Research Institutes, Governmental Bodies, Market Research Firms and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Capecitabine market on the basis of product [500 mg and 150 mg] , application [Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Capecitabine market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Capecitabine industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Roche Holding AG (Switzerland), Mylan (United States), Hikma Pharmaceuticals (United Kingdom), Reliance Group (India) and Hetero (India).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Capecitabine market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • 500 mg
  • 150 mg
By Application
  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
By Drug Formulation
  • Tablets
  • Capsule

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population
      • 3.2.2. Rise in Healthcare Expenditure and an Increase in Investment in Cancer Treatment or Assisted Programs by Governments
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Consumers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Capecitabine, by Type, Application, Drug Formulation and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Capecitabine (Value)
      • 5.2.1. Global Capecitabine by: Type (Value)
        • 5.2.1.1. 500 mg
        • 5.2.1.2. 150 mg
      • 5.2.2. Global Capecitabine by: Application (Value)
        • 5.2.2.1. Colon Cancer
        • 5.2.2.2. Rectal Cancer
        • 5.2.2.3. Breast Cancer
        • 5.2.2.4. Gastric Cancer
        • 5.2.2.5. Others
      • 5.2.3. Global Capecitabine by: Drug Formulation (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. Capsule
      • 5.2.4. Global Capecitabine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Capecitabine (Volume)
      • 5.3.1. Global Capecitabine by: Type (Volume)
        • 5.3.1.1. 500 mg
        • 5.3.1.2. 150 mg
      • 5.3.2. Global Capecitabine by: Application (Volume)
        • 5.3.2.1. Colon Cancer
        • 5.3.2.2. Rectal Cancer
        • 5.3.2.3. Breast Cancer
        • 5.3.2.4. Gastric Cancer
        • 5.3.2.5. Others
      • 5.3.3. Global Capecitabine by: Drug Formulation (Volume)
        • 5.3.3.1. Tablets
        • 5.3.3.2. Capsule
      • 5.3.4. Global Capecitabine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Capecitabine (Price)
      • 5.4.1. Global Capecitabine by: Type (Price)
  • 6. Capecitabine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dr Reddy Laboratories Ltd (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fresenius SE & Co. KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cipla Inc. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genentech, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ranbaxy Laboratories Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Zentiva N.V. (Czechia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharma B.V. (Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Accord Healthcare Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Capecitabine Sale, by Type, Application, Drug Formulation and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Capecitabine (Value)
      • 7.2.1. Global Capecitabine by: Type (Value)
        • 7.2.1.1. 500 mg
        • 7.2.1.2. 150 mg
      • 7.2.2. Global Capecitabine by: Application (Value)
        • 7.2.2.1. Colon Cancer
        • 7.2.2.2. Rectal Cancer
        • 7.2.2.3. Breast Cancer
        • 7.2.2.4. Gastric Cancer
        • 7.2.2.5. Others
      • 7.2.3. Global Capecitabine by: Drug Formulation (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. Capsule
      • 7.2.4. Global Capecitabine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Capecitabine (Volume)
      • 7.3.1. Global Capecitabine by: Type (Volume)
        • 7.3.1.1. 500 mg
        • 7.3.1.2. 150 mg
      • 7.3.2. Global Capecitabine by: Application (Volume)
        • 7.3.2.1. Colon Cancer
        • 7.3.2.2. Rectal Cancer
        • 7.3.2.3. Breast Cancer
        • 7.3.2.4. Gastric Cancer
        • 7.3.2.5. Others
      • 7.3.3. Global Capecitabine by: Drug Formulation (Volume)
        • 7.3.3.1. Tablets
        • 7.3.3.2. Capsule
      • 7.3.4. Global Capecitabine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Capecitabine (Price)
      • 7.4.1. Global Capecitabine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Capecitabine: by Type(USD Million)
  • Table 2. Capecitabine 500 mg , by Region USD Million (2013-2018)
  • Table 3. Capecitabine 150 mg , by Region USD Million (2013-2018)
  • Table 4. Capecitabine: by Application(USD Million)
  • Table 5. Capecitabine Colon Cancer , by Region USD Million (2013-2018)
  • Table 6. Capecitabine Rectal Cancer , by Region USD Million (2013-2018)
  • Table 7. Capecitabine Breast Cancer , by Region USD Million (2013-2018)
  • Table 8. Capecitabine Gastric Cancer , by Region USD Million (2013-2018)
  • Table 9. Capecitabine Others , by Region USD Million (2013-2018)
  • Table 10. Capecitabine: by Drug Formulation(USD Million)
  • Table 11. Capecitabine Tablets , by Region USD Million (2013-2018)
  • Table 12. Capecitabine Capsule , by Region USD Million (2013-2018)
  • Table 13. South America Capecitabine, by Country USD Million (2013-2018)
  • Table 14. South America Capecitabine, by Type USD Million (2013-2018)
  • Table 15. South America Capecitabine, by Application USD Million (2013-2018)
  • Table 16. South America Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 17. Brazil Capecitabine, by Type USD Million (2013-2018)
  • Table 18. Brazil Capecitabine, by Application USD Million (2013-2018)
  • Table 19. Brazil Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 20. Argentina Capecitabine, by Type USD Million (2013-2018)
  • Table 21. Argentina Capecitabine, by Application USD Million (2013-2018)
  • Table 22. Argentina Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 23. Rest of South America Capecitabine, by Type USD Million (2013-2018)
  • Table 24. Rest of South America Capecitabine, by Application USD Million (2013-2018)
  • Table 25. Rest of South America Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 26. Asia Pacific Capecitabine, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Capecitabine, by Type USD Million (2013-2018)
  • Table 28. Asia Pacific Capecitabine, by Application USD Million (2013-2018)
  • Table 29. Asia Pacific Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 30. China Capecitabine, by Type USD Million (2013-2018)
  • Table 31. China Capecitabine, by Application USD Million (2013-2018)
  • Table 32. China Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 33. Japan Capecitabine, by Type USD Million (2013-2018)
  • Table 34. Japan Capecitabine, by Application USD Million (2013-2018)
  • Table 35. Japan Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 36. India Capecitabine, by Type USD Million (2013-2018)
  • Table 37. India Capecitabine, by Application USD Million (2013-2018)
  • Table 38. India Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 39. South Korea Capecitabine, by Type USD Million (2013-2018)
  • Table 40. South Korea Capecitabine, by Application USD Million (2013-2018)
  • Table 41. South Korea Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 42. Taiwan Capecitabine, by Type USD Million (2013-2018)
  • Table 43. Taiwan Capecitabine, by Application USD Million (2013-2018)
  • Table 44. Taiwan Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 45. Australia Capecitabine, by Type USD Million (2013-2018)
  • Table 46. Australia Capecitabine, by Application USD Million (2013-2018)
  • Table 47. Australia Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Capecitabine, by Type USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Capecitabine, by Application USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 51. Europe Capecitabine, by Country USD Million (2013-2018)
  • Table 52. Europe Capecitabine, by Type USD Million (2013-2018)
  • Table 53. Europe Capecitabine, by Application USD Million (2013-2018)
  • Table 54. Europe Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 55. Germany Capecitabine, by Type USD Million (2013-2018)
  • Table 56. Germany Capecitabine, by Application USD Million (2013-2018)
  • Table 57. Germany Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 58. France Capecitabine, by Type USD Million (2013-2018)
  • Table 59. France Capecitabine, by Application USD Million (2013-2018)
  • Table 60. France Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 61. Italy Capecitabine, by Type USD Million (2013-2018)
  • Table 62. Italy Capecitabine, by Application USD Million (2013-2018)
  • Table 63. Italy Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 64. United Kingdom Capecitabine, by Type USD Million (2013-2018)
  • Table 65. United Kingdom Capecitabine, by Application USD Million (2013-2018)
  • Table 66. United Kingdom Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 67. Netherlands Capecitabine, by Type USD Million (2013-2018)
  • Table 68. Netherlands Capecitabine, by Application USD Million (2013-2018)
  • Table 69. Netherlands Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 70. Rest of Europe Capecitabine, by Type USD Million (2013-2018)
  • Table 71. Rest of Europe Capecitabine, by Application USD Million (2013-2018)
  • Table 72. Rest of Europe Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 73. MEA Capecitabine, by Country USD Million (2013-2018)
  • Table 74. MEA Capecitabine, by Type USD Million (2013-2018)
  • Table 75. MEA Capecitabine, by Application USD Million (2013-2018)
  • Table 76. MEA Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 77. Middle East Capecitabine, by Type USD Million (2013-2018)
  • Table 78. Middle East Capecitabine, by Application USD Million (2013-2018)
  • Table 79. Middle East Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 80. Africa Capecitabine, by Type USD Million (2013-2018)
  • Table 81. Africa Capecitabine, by Application USD Million (2013-2018)
  • Table 82. Africa Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 83. North America Capecitabine, by Country USD Million (2013-2018)
  • Table 84. North America Capecitabine, by Type USD Million (2013-2018)
  • Table 85. North America Capecitabine, by Application USD Million (2013-2018)
  • Table 86. North America Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 87. United States Capecitabine, by Type USD Million (2013-2018)
  • Table 88. United States Capecitabine, by Application USD Million (2013-2018)
  • Table 89. United States Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 90. Canada Capecitabine, by Type USD Million (2013-2018)
  • Table 91. Canada Capecitabine, by Application USD Million (2013-2018)
  • Table 92. Canada Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 93. Mexico Capecitabine, by Type USD Million (2013-2018)
  • Table 94. Mexico Capecitabine, by Application USD Million (2013-2018)
  • Table 95. Mexico Capecitabine, by Drug Formulation USD Million (2013-2018)
  • Table 96. Capecitabine Sales: by Type(K Unit)
  • Table 97. Capecitabine Sales 500 mg , by Region K Unit (2013-2018)
  • Table 98. Capecitabine Sales 150 mg , by Region K Unit (2013-2018)
  • Table 99. Capecitabine Sales: by Application(K Unit)
  • Table 100. Capecitabine Sales Colon Cancer , by Region K Unit (2013-2018)
  • Table 101. Capecitabine Sales Rectal Cancer , by Region K Unit (2013-2018)
  • Table 102. Capecitabine Sales Breast Cancer , by Region K Unit (2013-2018)
  • Table 103. Capecitabine Sales Gastric Cancer , by Region K Unit (2013-2018)
  • Table 104. Capecitabine Sales Others , by Region K Unit (2013-2018)
  • Table 105. Capecitabine Sales: by Drug Formulation(K Unit)
  • Table 106. Capecitabine Sales Tablets , by Region K Unit (2013-2018)
  • Table 107. Capecitabine Sales Capsule , by Region K Unit (2013-2018)
  • Table 108. South America Capecitabine Sales, by Country K Unit (2013-2018)
  • Table 109. South America Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 110. South America Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 111. South America Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 112. Brazil Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 113. Brazil Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 114. Brazil Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 115. Argentina Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 116. Argentina Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 117. Argentina Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 118. Rest of South America Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 119. Rest of South America Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 120. Rest of South America Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 121. Asia Pacific Capecitabine Sales, by Country K Unit (2013-2018)
  • Table 122. Asia Pacific Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 123. Asia Pacific Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 124. Asia Pacific Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 125. China Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 126. China Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 127. China Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 128. Japan Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 129. Japan Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 130. Japan Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 131. India Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 132. India Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 133. India Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 134. South Korea Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 135. South Korea Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 136. South Korea Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 137. Taiwan Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 138. Taiwan Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 139. Taiwan Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 140. Australia Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 141. Australia Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 142. Australia Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 143. Rest of Asia-Pacific Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 144. Rest of Asia-Pacific Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 145. Rest of Asia-Pacific Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 146. Europe Capecitabine Sales, by Country K Unit (2013-2018)
  • Table 147. Europe Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 148. Europe Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 149. Europe Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 150. Germany Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 151. Germany Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 152. Germany Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 153. France Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 154. France Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 155. France Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 156. Italy Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 157. Italy Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 158. Italy Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 159. United Kingdom Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 160. United Kingdom Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 161. United Kingdom Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 162. Netherlands Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 163. Netherlands Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 164. Netherlands Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 165. Rest of Europe Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 166. Rest of Europe Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 167. Rest of Europe Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 168. MEA Capecitabine Sales, by Country K Unit (2013-2018)
  • Table 169. MEA Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 170. MEA Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 171. MEA Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 172. Middle East Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 173. Middle East Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 174. Middle East Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 175. Africa Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 176. Africa Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 177. Africa Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 178. North America Capecitabine Sales, by Country K Unit (2013-2018)
  • Table 179. North America Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 180. North America Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 181. North America Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 182. United States Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 183. United States Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 184. United States Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 185. Canada Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 186. Canada Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 187. Canada Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 188. Mexico Capecitabine Sales, by Type K Unit (2013-2018)
  • Table 189. Mexico Capecitabine Sales, by Application K Unit (2013-2018)
  • Table 190. Mexico Capecitabine Sales, by Drug Formulation K Unit (2013-2018)
  • Table 191. Capecitabine: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Capecitabine: by Type(USD Million)
  • Table 203. Capecitabine 500 mg , by Region USD Million (2019-2024)
  • Table 204. Capecitabine 150 mg , by Region USD Million (2019-2024)
  • Table 205. Capecitabine: by Application(USD Million)
  • Table 206. Capecitabine Colon Cancer , by Region USD Million (2019-2024)
  • Table 207. Capecitabine Rectal Cancer , by Region USD Million (2019-2024)
  • Table 208. Capecitabine Breast Cancer , by Region USD Million (2019-2024)
  • Table 209. Capecitabine Gastric Cancer , by Region USD Million (2019-2024)
  • Table 210. Capecitabine Others , by Region USD Million (2019-2024)
  • Table 211. Capecitabine: by Drug Formulation(USD Million)
  • Table 212. Capecitabine Tablets , by Region USD Million (2019-2024)
  • Table 213. Capecitabine Capsule , by Region USD Million (2019-2024)
  • Table 214. South America Capecitabine, by Country USD Million (2019-2024)
  • Table 215. South America Capecitabine, by Type USD Million (2019-2024)
  • Table 216. South America Capecitabine, by Application USD Million (2019-2024)
  • Table 217. South America Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 218. Brazil Capecitabine, by Type USD Million (2019-2024)
  • Table 219. Brazil Capecitabine, by Application USD Million (2019-2024)
  • Table 220. Brazil Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 221. Argentina Capecitabine, by Type USD Million (2019-2024)
  • Table 222. Argentina Capecitabine, by Application USD Million (2019-2024)
  • Table 223. Argentina Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 224. Rest of South America Capecitabine, by Type USD Million (2019-2024)
  • Table 225. Rest of South America Capecitabine, by Application USD Million (2019-2024)
  • Table 226. Rest of South America Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 227. Asia Pacific Capecitabine, by Country USD Million (2019-2024)
  • Table 228. Asia Pacific Capecitabine, by Type USD Million (2019-2024)
  • Table 229. Asia Pacific Capecitabine, by Application USD Million (2019-2024)
  • Table 230. Asia Pacific Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 231. China Capecitabine, by Type USD Million (2019-2024)
  • Table 232. China Capecitabine, by Application USD Million (2019-2024)
  • Table 233. China Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 234. Japan Capecitabine, by Type USD Million (2019-2024)
  • Table 235. Japan Capecitabine, by Application USD Million (2019-2024)
  • Table 236. Japan Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 237. India Capecitabine, by Type USD Million (2019-2024)
  • Table 238. India Capecitabine, by Application USD Million (2019-2024)
  • Table 239. India Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 240. South Korea Capecitabine, by Type USD Million (2019-2024)
  • Table 241. South Korea Capecitabine, by Application USD Million (2019-2024)
  • Table 242. South Korea Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 243. Taiwan Capecitabine, by Type USD Million (2019-2024)
  • Table 244. Taiwan Capecitabine, by Application USD Million (2019-2024)
  • Table 245. Taiwan Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 246. Australia Capecitabine, by Type USD Million (2019-2024)
  • Table 247. Australia Capecitabine, by Application USD Million (2019-2024)
  • Table 248. Australia Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 249. Rest of Asia-Pacific Capecitabine, by Type USD Million (2019-2024)
  • Table 250. Rest of Asia-Pacific Capecitabine, by Application USD Million (2019-2024)
  • Table 251. Rest of Asia-Pacific Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 252. Europe Capecitabine, by Country USD Million (2019-2024)
  • Table 253. Europe Capecitabine, by Type USD Million (2019-2024)
  • Table 254. Europe Capecitabine, by Application USD Million (2019-2024)
  • Table 255. Europe Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 256. Germany Capecitabine, by Type USD Million (2019-2024)
  • Table 257. Germany Capecitabine, by Application USD Million (2019-2024)
  • Table 258. Germany Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 259. France Capecitabine, by Type USD Million (2019-2024)
  • Table 260. France Capecitabine, by Application USD Million (2019-2024)
  • Table 261. France Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 262. Italy Capecitabine, by Type USD Million (2019-2024)
  • Table 263. Italy Capecitabine, by Application USD Million (2019-2024)
  • Table 264. Italy Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 265. United Kingdom Capecitabine, by Type USD Million (2019-2024)
  • Table 266. United Kingdom Capecitabine, by Application USD Million (2019-2024)
  • Table 267. United Kingdom Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 268. Netherlands Capecitabine, by Type USD Million (2019-2024)
  • Table 269. Netherlands Capecitabine, by Application USD Million (2019-2024)
  • Table 270. Netherlands Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 271. Rest of Europe Capecitabine, by Type USD Million (2019-2024)
  • Table 272. Rest of Europe Capecitabine, by Application USD Million (2019-2024)
  • Table 273. Rest of Europe Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 274. MEA Capecitabine, by Country USD Million (2019-2024)
  • Table 275. MEA Capecitabine, by Type USD Million (2019-2024)
  • Table 276. MEA Capecitabine, by Application USD Million (2019-2024)
  • Table 277. MEA Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 278. Middle East Capecitabine, by Type USD Million (2019-2024)
  • Table 279. Middle East Capecitabine, by Application USD Million (2019-2024)
  • Table 280. Middle East Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 281. Africa Capecitabine, by Type USD Million (2019-2024)
  • Table 282. Africa Capecitabine, by Application USD Million (2019-2024)
  • Table 283. Africa Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 284. North America Capecitabine, by Country USD Million (2019-2024)
  • Table 285. North America Capecitabine, by Type USD Million (2019-2024)
  • Table 286. North America Capecitabine, by Application USD Million (2019-2024)
  • Table 287. North America Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 288. United States Capecitabine, by Type USD Million (2019-2024)
  • Table 289. United States Capecitabine, by Application USD Million (2019-2024)
  • Table 290. United States Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 291. Canada Capecitabine, by Type USD Million (2019-2024)
  • Table 292. Canada Capecitabine, by Application USD Million (2019-2024)
  • Table 293. Canada Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 294. Mexico Capecitabine, by Type USD Million (2019-2024)
  • Table 295. Mexico Capecitabine, by Application USD Million (2019-2024)
  • Table 296. Mexico Capecitabine, by Drug Formulation USD Million (2019-2024)
  • Table 297. Capecitabine Sales: by Type(K Unit)
  • Table 298. Capecitabine Sales 500 mg , by Region K Unit (2019-2024)
  • Table 299. Capecitabine Sales 150 mg , by Region K Unit (2019-2024)
  • Table 300. Capecitabine Sales: by Application(K Unit)
  • Table 301. Capecitabine Sales Colon Cancer , by Region K Unit (2019-2024)
  • Table 302. Capecitabine Sales Rectal Cancer , by Region K Unit (2019-2024)
  • Table 303. Capecitabine Sales Breast Cancer , by Region K Unit (2019-2024)
  • Table 304. Capecitabine Sales Gastric Cancer , by Region K Unit (2019-2024)
  • Table 305. Capecitabine Sales Others , by Region K Unit (2019-2024)
  • Table 306. Capecitabine Sales: by Drug Formulation(K Unit)
  • Table 307. Capecitabine Sales Tablets , by Region K Unit (2019-2024)
  • Table 308. Capecitabine Sales Capsule , by Region K Unit (2019-2024)
  • Table 309. South America Capecitabine Sales, by Country K Unit (2019-2024)
  • Table 310. South America Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 311. South America Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 312. South America Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 313. Brazil Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 314. Brazil Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 315. Brazil Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 316. Argentina Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 317. Argentina Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 318. Argentina Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 319. Rest of South America Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 320. Rest of South America Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 321. Rest of South America Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 322. Asia Pacific Capecitabine Sales, by Country K Unit (2019-2024)
  • Table 323. Asia Pacific Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 324. Asia Pacific Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 325. Asia Pacific Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 326. China Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 327. China Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 328. China Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 329. Japan Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 330. Japan Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 331. Japan Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 332. India Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 333. India Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 334. India Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 335. South Korea Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 336. South Korea Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 337. South Korea Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 338. Taiwan Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 339. Taiwan Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 340. Taiwan Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 341. Australia Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 342. Australia Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 343. Australia Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 344. Rest of Asia-Pacific Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 345. Rest of Asia-Pacific Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 346. Rest of Asia-Pacific Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 347. Europe Capecitabine Sales, by Country K Unit (2019-2024)
  • Table 348. Europe Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 349. Europe Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 350. Europe Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 351. Germany Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 352. Germany Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 353. Germany Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 354. France Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 355. France Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 356. France Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 357. Italy Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 358. Italy Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 359. Italy Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 360. United Kingdom Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 361. United Kingdom Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 362. United Kingdom Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 363. Netherlands Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 364. Netherlands Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 365. Netherlands Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 366. Rest of Europe Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 367. Rest of Europe Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 368. Rest of Europe Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 369. MEA Capecitabine Sales, by Country K Unit (2019-2024)
  • Table 370. MEA Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 371. MEA Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 372. MEA Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 373. Middle East Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 374. Middle East Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 375. Middle East Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 376. Africa Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 377. Africa Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 378. Africa Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 379. North America Capecitabine Sales, by Country K Unit (2019-2024)
  • Table 380. North America Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 381. North America Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 382. North America Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 383. United States Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 384. United States Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 385. United States Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 386. Canada Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 387. Canada Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 388. Canada Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 389. Mexico Capecitabine Sales, by Type K Unit (2019-2024)
  • Table 390. Mexico Capecitabine Sales, by Application K Unit (2019-2024)
  • Table 391. Mexico Capecitabine Sales, by Drug Formulation K Unit (2019-2024)
  • Table 392. Capecitabine: by Type(USD/Units)
  • Table 393. Research Programs/Design for This Report
  • Table 394. Key Data Information from Secondary Sources
  • Table 395. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Capecitabine: by Type USD Million (2013-2018)
  • Figure 5. Global Capecitabine: by Application USD Million (2013-2018)
  • Figure 6. Global Capecitabine: by Drug Formulation USD Million (2013-2018)
  • Figure 7. South America Capecitabine Share (%), by Country
  • Figure 8. Asia Pacific Capecitabine Share (%), by Country
  • Figure 9. Europe Capecitabine Share (%), by Country
  • Figure 10. MEA Capecitabine Share (%), by Country
  • Figure 11. North America Capecitabine Share (%), by Country
  • Figure 12. Global Capecitabine: by Type K Unit (2013-2018)
  • Figure 13. Global Capecitabine: by Application K Unit (2013-2018)
  • Figure 14. Global Capecitabine: by Drug Formulation K Unit (2013-2018)
  • Figure 15. South America Capecitabine Share (%), by Country
  • Figure 16. Asia Pacific Capecitabine Share (%), by Country
  • Figure 17. Europe Capecitabine Share (%), by Country
  • Figure 18. MEA Capecitabine Share (%), by Country
  • Figure 19. North America Capecitabine Share (%), by Country
  • Figure 20. Global Capecitabine: by Type USD/Units (2013-2018)
  • Figure 21. Global Capecitabine share by Players 2018 (%)
  • Figure 22. Global Capecitabine share by Players (Top 3) 2018(%)
  • Figure 23. Global Capecitabine share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Dr Reddy Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 26. Dr Reddy Laboratories Ltd (India) Revenue: by Geography 2018
  • Figure 27. Fresenius SE & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Fresenius SE & Co. KGaA (Germany) Revenue: by Geography 2018
  • Figure 29. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla Inc. (India) Revenue: by Geography 2018
  • Figure 31. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genentech, Inc. (United States) Revenue: by Geography 2018
  • Figure 33. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2018
  • Figure 35. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Sandoz (Germany) Revenue: by Geography 2018
  • Figure 37. Ranbaxy Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 38. Ranbaxy Laboratories Ltd. (India) Revenue: by Geography 2018
  • Figure 39. Zentiva N.V. (Czechia) Revenue, Net Income and Gross profit
  • Figure 40. Zentiva N.V. (Czechia) Revenue: by Geography 2018
  • Figure 41. Teva Pharma B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 42. Teva Pharma B.V. (Netherlands) Revenue: by Geography 2018
  • Figure 43. Accord Healthcare Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 44. Accord Healthcare Ltd. (India) Revenue: by Geography 2018
  • Figure 45. Global Capecitabine: by Type USD Million (2019-2024)
  • Figure 46. Global Capecitabine: by Application USD Million (2019-2024)
  • Figure 47. Global Capecitabine: by Drug Formulation USD Million (2019-2024)
  • Figure 48. South America Capecitabine Share (%), by Country
  • Figure 49. Asia Pacific Capecitabine Share (%), by Country
  • Figure 50. Europe Capecitabine Share (%), by Country
  • Figure 51. MEA Capecitabine Share (%), by Country
  • Figure 52. North America Capecitabine Share (%), by Country
  • Figure 53. Global Capecitabine: by Type K Unit (2019-2024)
  • Figure 54. Global Capecitabine: by Application K Unit (2019-2024)
  • Figure 55. Global Capecitabine: by Drug Formulation K Unit (2019-2024)
  • Figure 56. South America Capecitabine Share (%), by Country
  • Figure 57. Asia Pacific Capecitabine Share (%), by Country
  • Figure 58. Europe Capecitabine Share (%), by Country
  • Figure 59. MEA Capecitabine Share (%), by Country
  • Figure 60. North America Capecitabine Share (%), by Country
  • Figure 61. Global Capecitabine: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Dr Reddy Laboratories Ltd (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Cipla Inc. (India)
  • Genentech, Inc. (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Sandoz (Germany)
  • Ranbaxy Laboratories Ltd. (India)
  • Zentiva N.V. (Czechia)
  • Teva Pharma B.V. (Netherlands)
  • Accord Healthcare Ltd. (India)
Additional players considered in the study are as follows:
Roche Holding AG (Switzerland) , Mylan (United States) , Hikma Pharmaceuticals (United Kingdom) , Reliance Group (India) , Hetero (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation